Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia

Elena Ceccacci; Saverio Minucci

doi:10.1038/bjc.2016.36

Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia

Elena Ceccacci, Saverio Minucci

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.

Original language	English
Pages (from-to)	605-611
Number of pages	7
Journal	British Journal of Cancer
Volume	114
Issue number	6
DOIs	https://doi.org/10.1038/bjc.2016.36
Publication status	Published - Mar 15 2016

Keywords

APL
cancer stem cells
epigenetics
HDACi
histone deacetylases
leukaemia

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1038/bjc.2016.36

Cite this

@article{fb913b6a748a4fd5886941b79bfc1d8c,

title = "Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia",

abstract = "Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.",

keywords = "APL, cancer stem cells, epigenetics, HDACi, histone deacetylases, leukaemia",

author = "Elena Ceccacci and Saverio Minucci",

year = "2016",

month = mar,

day = "15",

doi = "10.1038/bjc.2016.36",

language = "English",

volume = "114",

pages = "605--611",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Inhibition of histone deacetylases in cancer therapy

T2 - Lessons from leukaemia

AU - Ceccacci, Elena

AU - Minucci, Saverio

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.

AB - Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.

KW - APL

KW - cancer stem cells

KW - epigenetics

KW - HDACi

KW - histone deacetylases

KW - leukaemia

UR - http://www.scopus.com/inward/record.url?scp=84959140658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959140658&partnerID=8YFLogxK

U2 - 10.1038/bjc.2016.36

DO - 10.1038/bjc.2016.36

M3 - Article

AN - SCOPUS:84959140658

SN - 0007-0920

VL - 114

SP - 605

EP - 611

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 6

ER -

Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this